### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **FORM 10-Q**

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2007

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from \_\_\_\_\_\_ to \_\_\_\_\_

Commission file number: 0-25317

# **INVITROGEN CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of

incorporation or organization)

33-0373077 (I.R.S. Employer

Identification No.)

92008 (Zip Code)

1600 Faraday Avenue, Carlsbad, CA92(Address of principal executive offices)(ZipRegistrant s telephone number, including area code: (760) 603-7200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject

### Edgar Filing: INVITROGEN CORP - Form 10-Q

to such filing requirements for the past 90 days. Yes  $x = No^{-1}$ .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check One)

Large accelerated filer x Accelerated filer " Non-accelerated filer "

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes " or No x

As of November 1, 2007, 46,565,923 shares of the Registrant s Common Stock were outstanding.

#### PART I. FINANCIAL INFORMATION

### ITEM 1. Financial Statements

### INVITROGEN CORPORATION

### CONSOLIDATED BALANCE SHEETS

### (In thousands, except par value and share data)

	September 30, 2007 (Unaudited)	December 31, 2006	
ASSETS			
Current assets:			
Cash and cash equivalents	\$ 594,278	\$ 343,181	
Short-term investments	50,064	8,914	
Restricted cash and investments	4,112	4,393	
Trade accounts receivable, net of allowance for doubtful accounts of \$9,039 and \$6,968, respectively	192,841	177,510	
Inventories	164,979	146,400	
Deferred income tax assets	30,620	35,184	
Prepaid expenses and other current assets	25,952	25,022	
Total current assets	1,062,846	740,604	
Assets of discontinued operations (includes cash and cash equivalents of \$651 and \$23,712 as of			
September 30, 2007 and December 31, 2006, respectively)	651	262,575	
Long-term investments	753	2,850	
Property and equipment, net	285,502	275,419	
Goodwill	1,522,866	1,480,008	
Intangible assets, net	300,556	371,705	
Deferred income tax assets	7,318	1,858	
Other assets	46,920	47,856	
Total assets	\$ 3,227,412	\$ 3,182,875	
LIABILITIES AND STOCKHOLDERS EQUITY			
Current liabilities:			
Current portion of long-term debt	\$ 566	\$ 1,961	
Accounts payable	87,400	85,274	
Restructuring reserve	8,728	17,762	
Accrued expenses and other current liabilities	101,533	102,385	
Income taxes payable	10,865	20,704	
Total current liabilities	209,092	228,086	
Liabilities of discontinued operations	3,233	28,171	
Long-term debt	1,150,703	1,150,824	
Pension liabilities	40,288	38,444	
Deferred income tax liabilities	66,657	92,942	
Income taxes payable	27,011		
Other long-term obligations, deferred credits and reserves	14,558	13,981	

### Edgar Filing: INVITROGEN CORP - Form 10-Q

Total liabilities	1,511,542	1,552,448
Stockholders equity:		
Preferred stock; \$0.01 par value, 6,405,884 shares authorized; no shares issued or outstanding		
Common stock; \$0.01 par value, 125,000,000 shares authorized; 60,213,272 and 58,967,060 shares issued,		
respectively	602	590
Additional paid-in-capital	2,328,788	2,220,536
Accumulated other comprehensive income	98,028	34,994
Retained earnings	45,941	(54,680)
Less cost of treasury stock: 13,799,140 and 11,111,491, respectively	(757,489)	(571,013)
Total stockholders equity	1,715,870	1,630,427
Total liabilities and stockholders equity	\$ 3,227,412	\$ 3,182,875

See accompanying notes to unaudited consolidated financial statements.

2

### INVITROGEN CORPORATION

### CONSOLIDATED STATEMENTS OF OPERATIONS

### (In thousands, except per share data)

	e	ended Sep 2007	he three months d September 30, / 2006 (Unaudited)			For the nine months ended September 30, 2007 2006 (Unaudited)		
Revenues	\$ 2	14,959		284,197	\$ 0/	(Ona) 5,302		849,592
Cost of revenues		13,875		12,202		1,799		316,289
Purchased intangibles amortization		26,294		27,735		1,837		83,519
		20,294		21,155	0	1,057		05,519
Gross profit	1	74,790	1	44,260	52	1,666		449,784
Operating expenses:								
Sales and marketing		63,864		56,934		3,515		174,473
General and administrative		40,430		34,435	12	5,742		110,377
Research and development		28,571		26,250	8	4,620		79,738
Business integration costs		2,267		2,644		4,789		8,043
Total operating expenses	1	35,132	1	20,263	39	8,666		372,631
Operating income		39,658		23,997	12	3,000		77,153
Other income (expense):								
Interest income		7,713		7,200		9,613		21,416
Interest expense		(6,933)		(7,996)		1,061)		(24,374)
Other income (expense)		1,516		(1,405)		1,612		443
Total other income (expense), net		2,296		(2,201)		164		(2,515)
Income from continuing operations, before provision for income taxes		41,954 21,796		123,164			74,638	
Income tax provision	(	11,464)		(5,958)	(3	3,385)		(21,493)
Net income from continuing operations		30,490		15,838	8	9,779		53,145
Net income (loss) from discontinued operations, net of tax		506	(1	45,631)	1	2,361	(	144,040)
Net income	\$	30,996	\$(1	29,793)	\$ 10	2,140	\$	(90,895)
Basic earnings (loss) per common share:								
Net income from continuing operations	\$	0.66	\$	0.31	\$	1.92	\$	1.01
Net income (loss) from discontinued operations	\$	0.01	\$	(2.84)	\$	0.27	\$	(2.74)
Net income (loss)	\$	0.67	\$	(2.53)	\$	2.19	\$	(1.73)
Weighted average shares outstanding		46,315		51,271	4	6,710		52,499
Diluted earnings (loss) per common share:		10,515		51,271	-	5,710		52,779
Net income from continuing operations	\$	0.63	\$	0.30	\$	1.87	\$	0.99
Net income (loss) from discontinued operations	\$	0.05	\$	(2.77)	\$	0.26	\$	(2.66)
Net income (loss)	\$	0.64	\$	(2.47)	\$	2.13	\$	(1.67)
The mean (1055)	φ	0.04	Ψ	(2.47)	Ψ	2.13	φ	(1.07)
Weighted average shares outstanding		48,198		52,585	4	8,076		54,077

### Edgar Filing: INVITROGEN CORP - Form 10-Q

The accompanying notes are an integral part of these consolidated financial statements.

#### INVITROGEN CORPORATION

### CONSOLIDATED STATEMENTS OF CASH FLOWS

#### (In thousands)

	For the nine months	
	ended September 30, 2007 2006 (Unaudited)	
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income (loss)	\$ 102,140	\$ (90,895)
Adjustments to reconcile net income (loss) to net cash provided by operating activities, net of effects of businesses acquired and divested:		
Depreciation	27,745	29,810
Amortization of intangible assets	81,837	90,978
Impairment of goodwill		150,000
Amortization of deferred debt issue costs	1,081	1,842
Amortization of premiums on investments, net of accretion of discounts	36	(5,372)
Share-based compensation	35,526	36,529
Incremental tax benefits from stock options exercised	(5,191)	(2,616)
Deferred income taxes	1,215	(23,700)
Other non-cash adjustments	8,622	5,964
Changes in operating assets and liabilities:		
Trade accounts receivable	(13,059)	(3,114)
Inventories	(17,811)	(18,048)
Prepaid expenses and other current assets	22	3,499
Other assets	3,034	2,195
Accounts payable	2,227	(10,983)
Accrued expenses and other liabilities	(189)	(27,821)
Income taxes	(2,227)	(9,645)
Net cash provided by operating activities	225,008	128,623
CASH FLOWS FROM INVESTING ACTIVITIES:		
Maturities of available-for-sale securities	8,878	287,800
Purchases of available-for-sale securities	(50,064)	
Net cash paid for business combinations	(17,754)	(25,964)
Net cash received for divestitures	209,901	
Purchases of property and equipment	(35,858)	(44,381)
Proceeds from the sale of assets		10,645
Payments for intangible assets		(9,084)
Net cash provided by investing activities	115,103	219,016

### CASH FLOWS FROM FINANCING ACTIVITIES:

Principal payments on long-term obligations